Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid

• Published in: Stem cell research & therapy 2017-04, Vol.8 (1), p.100-100, Article 100
• Main Authors: Killer, Madeleine C, Nold, Philipp, Henkenius, Katharina, Fritz, Lea, Riedlinger, Tabea, Barckhausen, Christina, Frech, Miriam, Hackstein, Holger, Neubauer, Andreas, Brendel, Cornelia
• Format: Article
• Language: English
• Subjects: Acidification; Acids; Autoimmune diseases; Cell growth; Cell proliferation; Cell Proliferation - drug effects; Cells, Cultured; Clinical trials; Coculture Techniques; Cryopreservation; Cryoprotectors; Dimethyl sulfoxide; Dimethyl Sulfoxide - pharmacology; Electron transport; Fitness; Glucose; Glycolysis; Glycolysis - drug effects; Good Manufacturing Practice; Humans; Immunosuppression; Immunosuppressive agents; Immunosuppressive Agents - pharmacology; Laboratories; Leukocytes (mononuclear); Leukocytes, Mononuclear - cytology; Leukocytes, Mononuclear - metabolism; Lymphocytes T; Mesenchymal stem cells; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - drug effects; Mesenchymal Stromal Cells - metabolism; Mesenchyme; Metabolism; Mitochondria; Multiple sclerosis; Oxygen consumption; Peripheral blood mononuclear cells; Regeneration; Software; Stem cells; Studies; T cell receptors; T-cell; T-Lymphocytes - cytology; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Valproic acid; Valproic Acid - pharmacology
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-017-0553-y

Mesenchymal stem cells (MSCs) have entered the clinic as an Advanced Therapy Medicinal Product and are currently evaluated in a wide range of studies for tissue regeneration or in autoimmune disorders. Various efforts have been made to standardize and optimize expansion and manufacturing processes, but until now reliable potency assays for the final MSC product are lacking. Because recent findings suggest superior therapeutic efficacy of freshly administered MSCs in comparison with frozen cells, we sought to correlate the T-cell suppressive capacity of MSCs with their metabolic activity. Human MSCs were obtained from patients' bone fragments and were employed in coculture with peripheral blood mononuclear cells (PBMCs) in an allogeneic T-cell proliferation assay to measure immunosuppressive function. Metabolic activity of MSCs was measured in real time in terms of aerobic glycolysis quantified by the extracellular acidification rate and mitochondrial respiration quantified by the oxygen consumption rate. We show that MSC-induced suppression of T-cell proliferation was highly dependent on individual healthy donors' lymphocytes. Moreover, coculture with PBMCs increased the glycolytic and respiratory activity of MSCs considerably in a PBMC donor-dependent manner. The twofold to threefold enhancement of cell metabolism was accompanied by higher T-cell suppressive capacities of MSCs. The cryoprotectant dimethyl sulfoxide decreased metabolic and immunosuppressive performances of MSCs while valproic acid (VPA) increased their glycolytic, respiratory and T-cell suppressive capacity. Functional fitness of MSCs can be determined by measuring metabolic activity and can be enhanced by exposure to VPA. Pretesting the increment of metabolic activity upon interaction of donor MSCs with patient T-cells provides a rational approach for an individualized potency assay prior to MSC therapy.